User banner image
User avatar
  • admin

Posts

Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

CLEARWATER, Fla., April 23, 2026 (GLOBE NEWSWIRE) — Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold...

Baozun Releases 2025 Annual Sustainability Report

SHANGHAI, April 23, 2026 /PRNewswire/ — Baozun Inc. (Nasdaq: BZUN and HKEX: 9991) (“Baozun”, “we” or the “Company”), a leader, pioneer and digital commerce enabler...

WALOVI Signs Deals in Portugal & Spain, Moves from Scattered Footprints to Regional Deepening

LISBON, Portugal and MADRID, April 23, 2026 /PRNewswire/ — Riding the global wave of health-conscious consumption and Europe’s booming botanical beverage sector, Chinese brands are...

FarEye launches PILOT: The first fully integrated agentic AI dispatcher purpose-built for last-mile logistics

PILOT orchestrates 11 specialised AI agents across route planning, driver management, delivery recovery, and invoice reconciliation. India, 23/April/2026: FarEye, the global last-mile delivery technology company,...

COTY SHAREHOLDER NOTICE: Coty Inc. (COTY) Sued After Surprise Profit Decline, CEO Exit, and Withdrawn 2026 Guidance — Hagens Berman

SAN FRANCISCO, April 22, 2026 (GLOBE NEWSWIRE) — Coty Inc. (NYSE: COTY) faces a securities class action lawsuit which seeks to represent investors who purchased...

SkinHealth Systems Inc. Appoints Three New Independent Directors to Board

Kenneth Tripp, Dr. Sachin Shridharani, and E. Scott Beattie bring deep expertise in medical devices, aesthetic medicine, and global consumer brands LONG BEACH, Calif., April...

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) — Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd....

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical...

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged...

George Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhage

Significant lowering of systolic blood pressure of 9mmHg on top of background treatment maintained with GMRx2 over an average follow-up of 3 years Safety findings...